Table 3 Randomized acute ischemic syndrome trials for intravenous glycoprotein IIb/IIIa blockade

PURSUIT (10,948)

Eptifibatide

CP at rest or minimal exertion within

Death, and non-fatal MI, at 30 days

24 hours and either ischemic ECG

changes^* or CK-MB elevations

PRISM-PLUS (1915)

Tirofiban

CP at rest or minimal exertion within

Death, MI, or refractory ischemia, at 7 days

12 hours and either ischemic ECG

changes^* or CK-MB elevations

PRISM (3232)

Tirofiban

CP at rest or minimal exertion within

Death, MI or refractory ischemia, at 48 hours

24 hours and ischemic ECG changes^*

or CK-MB elevations or history of CAD or

positive stress test

PARAGON A (2282)

Lamifiban

CP at rest within 12 hours and ischemic

Death, and non-fatal MI, at 30 days

ECG changes^*

PARAGON B (5225)

Lamifiban

Patients within 12 hours of symptoms of

The composite incidence of death, MI, or SRI, at

acute myocardial ischemia and ECG changes^*

30 days

GUSTO IV-ACS (7800)

Abciximab

ACS within last 24 hours; > 5 min anginal

All-cause mortality, composite endpoint of death,

symptoms at rest, and either + troponin I/T,

or MI, at 30 days

or ST depression ≥ 0.5 mm